New cocktail of drugs shows promise for nasopharyngeal cancer

NCT ID NCT05305131

Recruiting now Disease control Sponsor: National University Hospital, Singapore Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding two immunotherapy drugs (pembrolizumab and bevacizumab) to standard chemotherapy (gemcitabine and cisplatin) works better for advanced nasopharyngeal cancer. About 50 participants will be randomly assigned to receive either the standard chemo or the new four-drug combo. The main goal is to see if the new combo leads to a complete metabolic response on a PET scan at 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine, cisplatin, pembrolizumab, and bevacizumab
What this could lead to: If successful, this combination could offer a more effective treatment for advanced nasopharyngeal cancer, potentially improving survival and reducing relapse.
What could go wrong: This is a small, early-phase trial (50 people). The added drugs may cause more side effects, and the results may not lead to a new standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma nasopharyngeal carcinoma, susceptibility to, 1 nasopharyngeal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CANCER

Contacts and locations

Locations

National University Hospital
RECRUITING

Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.